Efficacy and Tolerability of Initial Therapy With Single-Pill Combination Telmisartan/Hydrochlorothiazide 80/25 mg in Patients With Grade 2 or 3 Hypertension: A Multinational, Randomized, Double-Blind, Active-Controlled Trial

Clinical Therapeutics

Volumn 34, Issue 7, 2012, Pages 1613-1624

  Zhu, Dingliang L ^a   Bays, Harold ^b   Gao, Pingjin ^a   Mattheus, Michaela ^c   Voelker, Birgit ^c   Ruilope, Luis M ^d  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Hydrochlorothiazide; Initial therapy; Severe hypertension; Single pill combination; Telmisartan

Indexed keywords

HYDROCHLOROTHIAZIDE PLUS TELMISARTAN; PLACEBO; TELMISARTAN;

ADULT; AGED; ANXIETY; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PATIENT COMPLIANCE; PHASE 4 CLINICAL TRIAL; POLLAKISURIA; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SYNCOPE; SYSTOLIC BLOOD PRESSURE; UPPER RESPIRATORY TRACT INFECTION; URIC ACID BLOOD LEVEL;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84863811626     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.05.007     Document Type: Article

References (46)

1. Chobanian A.V., Bakris G.L., Black H.R., et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 42:1206-1252.
2. Mancia G., De B.G., Dominiczak A., et al. 2007 Guidelines for the management of arterial hypertension. J Hypertens 2007, 25:1105-1187. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).
3. Zhang Y., Zhang X., Liu L., Zanchetti A. Is a systolic blood pressure target <140 mmHg indicated in all hypertensives?. Subgroup analyses of findings from the randomized FEVER trial. Eur Heart J 2011, 32:1500-1508.
4. Ogihara T., Kikuchi K., Matsuoka H., et al. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2009). Hypertens Res 2009, 32:3-107.
5. 2010 Chinese guidelines for the management of hypertension [in Chinese]. Chin J Cardiol 2011, 39:579-616. Writing group of 2010 Chinese guidelines for the management of hypertension.
6. Tedesco M.A., Natale F., Calabro R. Effects of monotherapy and combination therapy on blood pressure control and target organ damage: a randomized prospective intervention study in a large population of hypertensive patients. J Clin Hypertens (Greenwich) 2006, 8:634-641.
7. Wald D.S., Law M., Morris J.K., et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009, 122:290-300.
8. Littlejohn T.W., Majul C.R., Olvera R., et al. Results of treatment with telmisartan-amlodipine in hypertensive patients. J Clin Hypertens (Greenwich) 2009, 11:207-213.
9. Littlejohn T.W., Majul C.R., Olvera R., et al. Telmisartan plus amlodipine in patients with moderate or severe hypertension: results from a subgroup analysis of a randomized, placebo-controlled, parallel-group, 4 × 4 factorial study. Postgrad Med 2009, 121:5-14.
10. Dahlof B., Sever P.S., Poulter N.R., et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005, 366:895-906.
11. Kjeldsen S.E., Jamerson K.A., Bakris G.L., et al. Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study. Blood Press 2008, 17:7-17.
12. Weber M.A., Bakris G.L., Dahlof B., et al. Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk. Blood Press 2007, 16:13-19.
13. Weber M.A., Bakris G.L., Jamerson K., et al. Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol 2010, 56:77-85.
14. Mancia G., Laurent S., Agabiti-Rosei E., et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009, 27:2121-2158.
15. White W.B., Punzi H.A., Murwin D., et al. Effects of the angiotensin II receptor blockers telmisartan vs valsartan in combination with hydrochlorothiazide 25 mg once daily for the treatment of hypertension. J Clin Hypertens (Greenwich) 2006, 8:626-633.
16. White W.B., Murwin D., Chrysant S.G., et al. Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial. Blood Press Monit 2008, 13:21-27.
17. White W.B., Davidai G., Schumacher H. Impact of angiotensin receptor blockade in combination with hydrochlorothiazide 25 mg in 2121 patients with stage 1-2 hypertension. J Hum Hypertens 2009, 23:817-825.
18. Allemann Y., Fraile B., Lambert M., et al. Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: the Exforge in Failure after Single Therapy (EX-FAST) study. J Clin Hypertens (Greenwich) 2008, 10:185-194.
19. Chrysant S.G., Melino M., Karki S., et al. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther 2008, 30:587-604.
20. Flack J.M., Hilkert R. Single-pill combination of amlodipine and valsartan in the management of hypertension. Expert Opin Pharmacother 2009, 10:1979-1994.
21. McGill J.B., Reilly P.A. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. Clin Ther 2001, 23:833-850.
22. Kaneshiro Y., Ichihara A., Sakoda M., et al. Add-on benefits of amlodipine and thiazide in nondiabetic chronic kidney disease stage 1/2 patients treated with valsartan. Kidney Blood Press Res 2009, 32:51-58.
23. Ichihara A., Kaneshiro Y., Takemitsu T., Sakoda M. Effects of amlodipine and valsartan on vascular damage and ambulatory blood pressure in untreated hypertensive patients. J Hum Hypertens 2006, 20:787-794.
24. Mazzolai L., Burnier M. Comparative safety and tolerability of angiotensin II receptor antagonists. Drug Saf 1999, 21:23-33.
25. Bangalore S., Kamalakkannan G., Parkar S., Messerli F.H. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007, 120:713-719.
26. Dickson M., Plauschinat C.A. Compliance with antihypertensive therapy in the elderly: a comparison of fixed-dose combination amlodipine/benazepril versus component-based free-combination therapy. Am J Cardiovasc Drugs 2008, 8:45-50.
27. Yusuf S., Teo K.K., Pogue J., et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008, 358:1547-1559.
28. ICH Harmonised Tripartite Guideline for Good Clinical Practice FDA Federal Register, Accessed February 20, 2011. http://www.ich.org.
29. Pickering T.G., Hall J.E., Appel L.J., et al. Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension 2005, 45:142-161.
30. Brown H., Prescott R. Applied Mixed Models in Medicine 2006, John Wiley & Sons Ltd, Chichester, United Kingdom. 2nd ed.
31. Dmitrienko A., Molenberghs G., Chuang-Stein C. Analysis of Clinical Trials Using SAS: A Practical Guide 2005, SAS Press.
32. Lewington S., Clarke R., Qizilbash N., et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360:1903-1913.
33. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981-2997.
34. Julius S., Kjeldsen S.E., Weber M., et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004, 363:2022-2031.
35. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the SHEP. JAMA 1991, 265:3255-3264. Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group.
36. Staessen J.A., Fagard R., Thijs L., et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997, 350:757-764. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.
37. Hansson L., Lindholm L.H., Ekbom T., et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999, 354:1751-1756.
38. Brown M.J., Palmer C.R., Castaigne A., et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000, 356:366-372.
39. Flack J.M., Nasser S.A., Levy P.D. Therapy of hypertension in African Americans. Am J Cardiovasc Drugs 2011, 11:83-92.
40. Destro M., Luckow A., Samson M., et al. Efficacy and safety of amlodipine/valsartan compared with amlodipine monotherapy in patients with stage 2 hypertension: a randomized, double-blind, multicenter study: the EX-EFFeCTS Study. J Am Soc Hypertens 2008, 2:294-302.
41. Lai W.T., Park J.E., Dongre N., Wang J. Efficacy, safety, and tolerability of valsartan/hydrochlorothiazide in Asian patients with essential hypertension. Adv Ther 2011, 28:427-438.
42. Huang J., Sun N.L., Hao Y.M., et al. Efficacy and tolerability of a single-pill combination of amlodipine/valsartan in Asian hypertensive patients not adequately controlled with valsartan monotherapy. Clin Exp Hypertens 2011, 33:179-186.
43. Ke Y., Zhu D., Hong H., et al. Efficacy and safety of a single-pill combination of amlodipine/valsartan in Asian hypertensive patients inadequately controlled with amlodipine monotherapy. Curr Med Res Opin 2010, 26:1705-1713.
44. Kita T., Yokota N., Ichiki Y., et al. One-year effectiveness and safety of open-label losartan/hydrochlorothiazide combination therapy in Japanese patients with hypertension uncontrolled with ARBs or ACE inhibitors. Hypertens Res 2010, 33:320-325.
45. Sun N.L., Zhu J.R., Zhao Y., Tu Y.M. Combination antihypertensive therapy with valsartan and hydrochlorothiazide in Chinese patients with mild-to-moderate hypertension. Curr Med Res Opin 2008, 24:2863-2871.
46. Schumacher H., Mancia G. The safety profile of telmisartan as monotherapy or combined with hydrochlorothiazide: a retrospective analysis of 50 studies. Blood Press Suppl 2008, 1:32-40.